Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
Fiche publication
Date publication
octobre 2016
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Safety issues are a major concern for patients considering treatments for inflammatory bowel disease (IBD). We performed a systematic review and meta-analysis to determine whether biologic agents affect the risk of infection or malignancy in adults with IBD.
Mots clés
Anti-TNF, Antibody, Cancer Risk Factor, Side Effect
Référence
Clin. Gastroenterol. Hepatol.. 2016 10;14(10):1385-1397.e10